Literature DB >> 25579056

Inflammatory Chemokines MIP-1δ and MIP-3α Are Involved in the Migration of Multipotent Mesenchymal Stromal Cells Induced by Hepatoma Cells.

Esma Lejmi1, Nadja Perriraz, Sophie Clément, Philippe Morel, Reto Baertschiger, Panayiotis Christofilopoulos, Raphael Meier, Domenico Bosco, Léo H Bühler, Carmen Gonelle-Gispert.   

Abstract

In vivo, bone marrow-derived multipotent mesenchymal stromal cells (MSC) have been identified at sites of tumors, suggesting that specific signals mobilize and activate MSC to migrate to areas surrounding tumors. The signals and migratory mechanisms that guide MSC are not well understood. Here, we investigated the migration of human MSC induced by conditioned medium of Huh-7 hepatoma cells (Huh-7 CM). Using a transwell migration system, we showed that human MSC migration was increased in the presence of Huh-7 CM. Using a human cytokine antibody array, we detected increased levels of MIP-1δ and MIP-3α in Huh-7 CM. Recombinant chemokines MIP-1δ and MIP-3α induced MSC migration. Anti-MIP-1δ and anti-MIP-3α antibodies added to Huh-7 CM decreased MSC migration, further suggesting that MIP-1δ and MIP-3α were implicated in the Huh-7 CM-induced MSC migration. By real-time polymerase chain reaction, we observed an absence of chemokine receptors CCR2 and CXCR2 and low expression of CCR1, CCR5, and CCR6 in MSC. Expression of these chemokine receptors was not regulated by Huh-7 CM. Furthermore, matrix metalloproteinase 1 (MMP-1) expression was strongly increased in MSC after incubation with Huh-7 CM, suggesting that MSC migration depends on MMP-1 activity. The signaling pathway MAPK/ERK was activated by Huh-7 CM but its inhibition by PD98059 did not impair Huh-7 CM-induced MSC migration. Further, long-term incubation of MSC with MIP-1δ increased α-smooth muscle actin expression, suggesting its implication in the Huh-7 CM-induced evolvement of MSC into myofibroblasts. In conclusion, we report that two inflammatory cytokines, MIP-1δ and MIP-3α, are able to increase MSC migration in vitro. These cytokines might be responsible for migration and evolvement of MSC into myofibroblasts around tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25579056      PMCID: PMC4425419          DOI: 10.1089/scd.2014.0176

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  84 in total

1.  Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium.

Authors:  Jing Huang; Zhiping Zhang; Jian Guo; Aiguo Ni; Arjun Deb; Lunan Zhang; Maria Mirotsou; Richard E Pratt; Victor J Dzau
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

2.  Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro.

Authors:  Feng Xu; Jinlong Shi; Bin Yu; Wei Ni; Xing Wu; Zhikai Gu
Journal:  Oncol Rep       Date:  2010-06       Impact factor: 3.906

3.  Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.

Authors:  Mariana G Garcia; Juan Bayo; Marcela F Bolontrade; Leonardo Sganga; Mariana Malvicini; Laura Alaniz; Jorge B Aquino; Esteban Fiore; Manglio M Rizzo; Andrés Rodriguez; Alicia Lorenti; Oscar Andriani; Osvaldo Podhajcer; Guillermo Mazzolini
Journal:  Mol Pharm       Date:  2011-08-19       Impact factor: 4.939

4.  Protein kinase C zeta regulates interleukin-8-mediated stromal-derived factor-1 expression and migration of human mesenchymal stromal cells.

Authors:  Sonia C Picinich; John W Glod; Debabrata Banerjee
Journal:  Exp Cell Res       Date:  2009-11-24       Impact factor: 3.905

5.  Migration of bone marrow-derived mesenchymal stem cells induced by tumor necrosis factor-alpha and its possible role in wound healing.

Authors:  Xiaobing Fu; Bing Han; Sa Cai; Yonghong Lei; Tongzhu Sun; Zhiyong Sheng
Journal:  Wound Repair Regen       Date:  2009 Mar-Apr       Impact factor: 3.617

6.  Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells.

Authors:  R M Dwyer; S M Potter-Beirne; K A Harrington; A J Lowery; E Hennessy; J M Murphy; F P Barry; T O'Brien; M J Kerin
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

7.  Upregulation of chemokine receptor expression by IL-10/IL-4 in adult neural stem cells.

Authors:  Yangtai Guan; Zhilong Jiang; Bogoljub Ciric; A M Rostami; Guang-Xian Zhang
Journal:  Exp Mol Pathol       Date:  2008-08-06       Impact factor: 3.362

8.  Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.

Authors:  Lata G Menon; Kathleen Kelly; Hong Wei Yang; Seung-Ki Kim; Peter M Black; Rona S Carroll
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

Review 9.  Multipotent mesenchymal stromal cell therapy and risk of malignancies.

Authors:  Federica Casiraghi; Giuseppe Remuzzi; Mauro Abbate; Norberto Perico
Journal:  Stem Cell Rev Rep       Date:  2013-02       Impact factor: 5.739

10.  Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human.

Authors:  Giselle Chamberlain; Karina Wright; Antal Rot; Brian Ashton; Jim Middleton
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  12 in total

1.  Adipose‑derived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells.

Authors:  Yanqing Chen; Yunfan He; Xuecen Wang; Feng Lu; Jianhua Gao
Journal:  Oncol Rep       Date:  2019-02-15       Impact factor: 3.906

Review 2.  Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy.

Authors:  Xianyao Wang; Xing Zhao; Zhixu He
Journal:  Oncol Lett       Date:  2021-01-28       Impact factor: 2.967

Review 3.  The role of mesenchymal stem cells in the occurrence, development, and therapy of hepatocellular carcinoma.

Authors:  Xiaoli Zhang; Na Li; Ying Zhu; Wei Wen
Journal:  Cancer Med       Date:  2022-01-03       Impact factor: 4.452

Review 4.  [Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy].

Authors:  Ai Li; Tianyuan Zhang; Jianqing Gao
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

Review 5.  Effects of matrix metalloproteinases on the fate of mesenchymal stem cells.

Authors:  Sami G Almalki; Devendra K Agrawal
Journal:  Stem Cell Res Ther       Date:  2016-09-09       Impact factor: 6.832

6.  Multipotent mesenchymal stromal cells enhance insulin secretion from human islets via N-cadherin interaction and prolong function of transplanted encapsulated islets in mice.

Authors:  Elisa Montanari; Raphael P H Meier; Redouan Mahou; Jörg D Seebach; Christine Wandrey; Sandrine Gerber-Lemaire; Leo H Buhler; Carmen Gonelle-Gispert
Journal:  Stem Cell Res Ther       Date:  2017-09-29       Impact factor: 6.832

Review 7.  Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment.

Authors:  Daria S Chulpanova; Kristina V Kitaeva; Leysan G Tazetdinova; Victoria James; Albert A Rizvanov; Valeriya V Solovyeva
Journal:  Front Pharmacol       Date:  2018-03-20       Impact factor: 5.810

8.  IL-8, GRO and MCP-1 produced by hepatocellular carcinoma microenvironment determine the migratory capacity of human bone marrow-derived mesenchymal stromal cells without affecting tumor aggressiveness.

Authors:  Guillermo D Mazzolini; Mariana G García; Juan Bayo; Alejandrina Real; Esteban J Fiore; Mariana Malvicini; Leonardo Sganga; Marcela Bolontrade; Oscar Andriani; Carolina Bizama; Cristóbal Fresno; Osvaldo Podhajcer; Elmer Fernandez; Manuel Gidekel
Journal:  Oncotarget       Date:  2016-06-25

Review 9.  Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy.

Authors:  Zeli Yin; Keqiu Jiang; Rui Li; Chengyong Dong; Liming Wang
Journal:  Mol Cancer       Date:  2018-12-28       Impact factor: 27.401

10.  CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.

Authors:  Naike Casagrande; Cinzia Borghese; Lydia Visser; Maurizio Mongiat; Alfonso Colombatti; Donatella Aldinucci
Journal:  Haematologica       Date:  2018-10-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.